docwirenews.com
Cure8 news brief
Why This Matters
This study provides real-world evidence about using upadacitinib as a maintenance therapy in children with refractory Crohn’s disease — a group with limited treatment options.
It reports both effectiveness (clinical and corticosteroid-free remission) and notable adverse events, which are important when weighing treatment decisions.
Who Should Pay Attention
Pediatric patients with refractory Crohn’s disease and their caregivers, pediatric gastroenterologists, clinicians managing patients who failed multiple biologics, and researchers studying JAK inhibitors in IBD.
Study Snapshot
Story typeResearch news
Evidence typeClinical study
Source depthFull source text
What To Know
This article summarizes a retrospective multicenter cohort (Porto Group/ESPGHAN) of 120 pediatric patients with refractory Crohn’s disease who received maintenance upadacitinib, primarily after prior biologic exposure.
Reported 52-week outcomes included rates of clinical remission and corticosteroid-free remission, some objective biomarker responses (CRP, fecal calprotectin), and adverse events including acne, hyperlipidemia, infections, and two serious events (severe acne and intestinal perforation). The source cites a J Crohns Colitis 2026 paper (Spencer et al.).
What the study appears to report: maintenance upadacitinib led to sustained clinical and corticosteroid-free remission in a majority of this highly pretreated pediatric cohort at 52 weeks, but nearly half experienced adverse events and a small number had serious complications.
The article notes authors’ caution that benefits should be weighed against AE risks. Practical tone: This is a summary of published observational data rather than a randomized trial. It reports safety signals that clinicians and families may want to discuss if considering upadacitinib for refractory pediatric Crohn’s disease.
The study population was heavily pretreated (most had prior biologics and many had failed vedolizumab and ustekinumab), which matters for how generalizable results may be.
Keep In Mind
The article summarizes a retrospective cohort (observational) study from multiple centers; this design can show associations but not prove causation. The population was heavily pretreated, which may limit applicability to treatment-naïve children. The original paper (J Crohns Colitis 2026; Spencer et al.) is cited for full methods and data.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical study
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationdocwirenews.com
Indexed viaGoogle News
Source typeWeb article
PublishedSep 24, 2026, 12:20 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Upadacitinib treatment in pediatric Crohn's disease: 52-week outcomes of an international multicenter retrospective cohort study from the pediatric IBD Porto Group of ESPGHAN.
This study gives real-world 52‑week data on upadacitinib maintenance in children with refractory Crohn's disease, showing meaningful remission rates but also notable adverse events. That balance is important for families...
A Real-World Study of Upadacitinib in Anti-TNF Refractory Crohn's Disease - Dove Medical Press
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
Upadacitinib Effective for Perianal Crohn's Disease | Docwire News
The study suggests upadacitinib may improve both symptoms and MRI‑documented healing of perianal fistulas in Crohn’s disease, offering a potential treatment option especially for patients who have not previously received...